Take CD19 as an example, the most widely used target in CAR-T therapy, which has been validated to be effective and safe to treat B-ALL, chronic lymphocytic leukemia (CLL), and B cell lymphoma. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.